Author

Paul J. Converse

Johns Hopkins UniversityORCID 0000-0002-1256-7464Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:mouse· 3 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

Eric L. NuermbergeriD· 3 shared Deepak V. AlmeidaiD· 2 shared Oliver D. KommiD· 2 shared Todd A. Black· 2 shared Adolfo García-Pérez· 1 shared Alain R. BaulardiD· 1 shared Alexander BergiD· 1 shared Ana Yepes· 1 shared

Activity by Year

2024-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

Eric L. NuermbergerORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

DDU384: A new preclinical candidate for the treatment of Tuberculosis

Simon R. Green, Kirsteen I. Buchanan, Helena I. Boshoff, Paul J. Koovits, Dinakaran Murugesan, Cristina De Cozar-Gallardo, Ana Yepes, Eik Hoffmann, Lisa M. Massoudi, Paul J. Converse, Oliver D. Komm, Laura Guijarro-López, Patricia Casado, Paul Scullion, Adolfo García-Pérez, , Laura A. T. Cleghorn

This paper identifies DDU384, a new compound with potent in vivo efficacy against tuberculosis in murine models, showing potential to improve current treatment options.

bioRxiv · Oct 27, 2026 · PreprintMicrobiology

Contribution of the novel oxazolidinone TBD09 (MK-7762) to regimens with bedaquiline and pretomanid in a mouse model of tuberculosis

Deepak V. Almeida, Paul J. Converse, Courtney Schill, Jin I. Lee, Micha Levi, Alexander Berg, Mdluli Khisi, Eric L. Nuermberger

This study evaluates TBD09's contribution to BPa-based tuberculosis regimens in mice, showing comparable bactericidal and sterilizing activity to linezolid with reduced toxicity.

bioRxiv · Sep 24, 2026 · PreprintMicrobiology

Contribution of telacebec to novel drug regimens in a murine tuberculosis model

Oliver D. Komm, Sandeep K. Tyagi, Andrew Jesse Garcia, Deepak V. Almeida, Yong Seok Chang, Si‐Yang Li, Jennie Ruelas Castillo, Paul J. Converse, Todd A. Black, Nader Fotouhi, Eric L. Nuermberger

This study evaluates telacebec's contribution to combination therapies against two M. tuberculosis strains in a murine model, finding synergistic effects against HN878 and antagonistic effects against H37Rv.

Antimicrobial Agents and Chemotherapy · Dec 9, 2024Peer-reviewedMicrobiology